Bafna Pharmaceuticals Limited — Important, 09-04-2025: Updates

M/s. SRJR Lifesciences LLP, a promoter of Bafna Pharmaceuticals Limited, has sold 31,45,296 equity shares, representing 13.30% of the company's share capital, through an Offer for Sale (OFS) on March 27 and 28, 2025. This move successfully reduced the promoter group's shareholding to 75%, enabling the company to meet the Minimum Public Shareholding (MPS) requirement of 25% effective April 2, 2025. This increase in public shareholding highlights the firm's commitment to compliance and could positively affect investor sentiment by enhancing liquidity and market participation. Investors should watch closely for how this adjustment in shareholding impacts future share performance and strategic initiatives.